| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| ln Vitro |
Tazanolast is an oral, active mast cell stabilizer that has been demonstrated to prevent experimental asthma, Schulz-Dyer reaction in isolated airway muscles, and passive cutaneous allergic reactions. However, it did not impede the contraction of IgE-induced histamine and leukotriene D4-induced muscles. Compound 48/80-induced protein kinase C from the cytosol translocates to the membrane portion of mast cells and produces inositol trisphosphate without directly inhibiting phospholipase C in mast cells. Compound 48/80-induced histamine release from mast cells and lung fragments (mediated or compound 48/80-induced).
|
|---|---|
| ln Vivo |
In a dose-dependent manner, tazanolast at dosages of 30, 100, or 300 mg/kg given prior to ozone exposure prevented ozone-induced airway hyperresponsiveness. Tazanolast given after exposure to ozone does not reduce airway hyperresponsiveness. Two hours after exposure, tazanolast had no discernible effect on the cellular distribution of bronchoalveolar lavage (BAL) cells. In guinea pigs, tazanolast dramatically reduces the hyperresponsiveness of the airways caused by ozone [1].
|
| References | |
| Additional Infomation |
Tazanolast is an organic molecular entity.
|
| Molecular Formula |
C13H15N5O3
|
|---|---|
| Molecular Weight |
289.29
|
| Exact Mass |
289.117
|
| CAS # |
82989-25-1
|
| PubChem CID |
5380
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.343g/cm3
|
| Index of Refraction |
1.604
|
| LogP |
1.221
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
21
|
| Complexity |
366
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C(NC1C=C(C2NN=NN=2)C=CC=1)=O)OCCCC
|
| InChi Key |
XQTARQNQIVVBRX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H15N5O3/c1-2-3-7-21-13(20)12(19)14-10-6-4-5-9(8-10)11-15-17-18-16-11/h4-6,8H,2-3,7H2,1H3,(H,14,19)(H,15,16,17,18)
|
| Chemical Name |
butyl 2-oxo-2-[3-(2H-tetrazol-5-yl)anilino]acetate
|
| Synonyms |
WP 833; WP-833; Tazanolast
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~66.67 mg/mL (~230.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4567 mL | 17.2837 mL | 34.5674 mL | |
| 5 mM | 0.6913 mL | 3.4567 mL | 6.9135 mL | |
| 10 mM | 0.3457 mL | 1.7284 mL | 3.4567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
